Gensight Biologics S.a annual operating expenses
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Operating Expenses Growth & History (SIGHT)
Gensight Biologics S.a's operating expenses was €11.1M for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €11.1M | −€7.4M | −40.04% |
| 2024 | 2024-12-31 | €18.4M | −€14.2M | −43.54% |
| 2023 | 2023-12-31 | €32.7M | −€41,000 | −0.13% |
| 2022 | 2022-12-31 | €32.7M | −€3.1M | −8.75% |
| 2021 | 2021-12-31 | €35.8M | €3.5M | +10.69% |
| 2020 | 2020-12-31 | €32.4M | — | — |
Gensight Biologics S.a operating expenses trends
Over the last five fiscal years, Gensight Biologics S.a's operating expenses decreased from €32.4M to €11.1M, a change of −€21.3M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
reported and calculated operating expenses
TickerStat uses operating expenses reported in company official filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...